Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery↑Improving
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Oversold Bounce setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $88.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Concentration risk — Supplier: particular sterilization facility.
Medtronic is a global healthcare technology company, headquartered in Galway, Ireland, operating four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — that develop and sell device-based medical therapies (pacemakers, defibrillators, spinal... Read more
Hold if already holding. Not a fresh buy at $88.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Concentration risk — Supplier: particular sterilization facility. Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic operates four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — selling device-based medical therapies including the Micra leadless pacemaker, Evolut TAVR valves, Hugo robotic-assisted surgery system, and MiniMed 780G insulin pump to healthcare systems and physicians in more than 150 countries. The company employs over 95,000 full-time employees, 44% based in the U.S. or Puerto Rico, and in May 2025 announced its intention to separate the Diabetes Operating Unit into an independent, publicly traded company within roughly 18 months.
Medtronic sells its devices principally to hospitals and physicians, who in turn bill Medicare, Medicaid, private insurers, and comparable non-U.S. government programs for reimbursement — a dynamic the company says shapes which products customers purchase and the prices they are willing to pay. The company manufactures the majority of its products itself at facilities worldwide but procures components, raw materials, and critical third-party services such as sterilization from numerous suppliers across multiple countries, seeking multiple sourcing options where possible; even so, certain components, raw materials, and services are obtained from sole suppliers for reasons of quality assurance, cost effectiveness, or availability. Growth has also come through acquisitions, divestitures, and third-party research-and-development funding arrangements, the most significant recent example being the planned separation of the Diabetes Operating Unit — which sells the MiniMed insulin pump and Guardian Connect and Simplera continuous glucose monitors — into its own publicly traded company.
Show full overview
Medtronic's manufacturing carries a facility-concentration risk distinct from its supplier base: several of its key products are manufactured or sterilized at a single particular facility with constrained capacity and limited options for alternate sterilization sites, and because licensing a replacement manufacturing or sterilization facility takes time, a disruption at that one location could halt production of the affected products rather than merely raising costs. That risk compounds a separate sole-supplier dependency the 10-K discloses for certain components, raw materials, and services chosen for quality, cost, or availability reasons rather than redundancy, with no named backup supplier disclosed for either exposure.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-26Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-09-26T04:01:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers10-K Item 1A: 'for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers.'
- HIGHSupplierparticular sterilization facility10-K Item 1A: 'several of our key products are manufactured or sterilized at a particular facility, with constrained capacity and limited options for alternate sterilization facilities.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $88.64, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole suppliers; Concentration risk — Supplier: particular sterilization facility. Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $94.35 (+6.4%), stop $84.66 (−4.7%), A.R:R 1.3:1. Score 6.4/10, moderate confidence.
Take-profit target: $94.35 (+6.4% upside). Target $94.35 (+6.4%), stop $84.66 (−4.7%), A.R:R 1.3:1. Stop-loss: $84.66.
Concentration risk — Supplier: sole suppliers; Concentration risk — Supplier: particular sterilization facility; Thin upside margin: 6.4%.
Medtronic plc. trades at a P/E of 21.8 (forward 13.8). TrendMatrix value score: 6.3/10. Verdict: Hold.
34 analysts cover MDT with a consensus score of 4.0/5. Average price target: $105.
What does Medtronic plc. do?Medtronic is a global healthcare technology company, headquartered in Galway, Ireland, operating four reportable...
Medtronic is a global healthcare technology company, headquartered in Galway, Ireland, operating four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — that develop and sell device-based medical therapies (pacemakers, defibrillators, spinal implants, surgical staplers, insulin pumps) to healthcare systems and physicians in more than 150 countries. The company employs over 95,000 people and in May 2025 announced plans to separate its Diabetes unit into an independent public company.